New Zealand Specialty Stores Stock News

The board of Scales Corporation Limited ( NZSE:SCL ) has announced that it will be paying its dividend of NZ$0.15 on...

Anyone interested in EROAD Limited ( NZSE:ERD ) should probably be aware that a company insider, David Kenneson...

When close to half the companies in New Zealand have price-to-earnings ratios (or "P/E's") below 18x, you may consider...

Ryman Healthcare (NZSE:RYM) just released half-year numbers that will make investors sit up. Revenue is climbing, but the company has shifted from a solid profit to a net loss. See our latest analysis for Ryman Healthcare. The NZ$2.88 share price reflects a mixed story, with a solid 90 day share price return of 15.66% but a steep year to date share price decline and weak multi year total shareholder returns. This hints that sentiment is only cautiously improving after the earnings setback. If...

Port of Tauranga Limited recently announced that the Minister for Infrastructure has accepted its request to refer the Stella Passage development resource consent application to the fast-track consenting process, running in parallel with the existing but paused application affected by a judicial review and legislative uncertainty. This alternative fast-track route is important because it aims to keep the Stella Passage project moving despite a legislative drafting error that has stalled the...

Key Insights Institutions' substantial holdings in Contact Energy implies that they have significant influence over the...

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Global markets have been experiencing a mix of optimism and caution, with major U.S. stock indexes advancing amid hopes for an interest rate cut from the Federal Reserve. As investors navigate these changing conditions, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities despite their somewhat outdated designation. With strong financial health, these stocks can defy expectations and present growth potential at lower price points, making them...

EBOS Group Limited's ( NZSE:EBO ) price-to-earnings (or "P/E") ratio of 23x might make it look like a sell right now...

Green Cross Health Limited ( NZSE:GXH ) recently posted some strong earnings, and the market responded positively. We...

Key Insights Fonterra Co-operative Group will host its Annual General Meeting on 11th of December CEO Miles Hurrell's...

With a median price-to-earnings (or "P/E") ratio of close to 18x in New Zealand, you could be forgiven for feeling...

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can...

Fisher & Paykel Healthcare has already reported half-year 2025 results showing sales of NZ$1,088.5 million and net income of NZ$213.0 million, alongside higher basic earnings per share and an increased interim dividend. The company also raised its full-year revenue and net profit guidance, signaling management confidence that recent operational momentum can continue. Next, we’ll explore how the upgraded full-year earnings guidance may influence Fisher & Paykel Healthcare’s existing...

Green Cross Health Limited ( NZSE:GXH ) will increase its dividend on the 18th of December to NZ$0.0353, which is 20...

Tower Limited ( NZSE:TWR ) came out with its full-year results last week, and we wanted to see how the business is...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

It looks like Green Cross Health Limited ( NZSE:GXH ) is about to go ex-dividend in the next 3 days. The ex-dividend...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

The recent earnings posted by Oceania Healthcare Limited ( NZSE:OCA ) were solid, but the stock didn't move as much as...

Last week saw the newest half-year earnings release from Fisher & Paykel Healthcare Corporation Limited ( NZSE:FPH...

Rakon (NZSE:RAK) just posted its H1 2026 results, reporting revenue of 62.004 million NZD and basic EPS of 0.0196 NZD. Looking back, the company has seen revenue go from 41.657 million NZD in H1 2025 to 66.756 million NZD in H2 2024 before reaching the latest figure. EPS moved from -0.046 NZD up to 0.018276 NZD, then to the current 0.0196 NZD. With these numbers out, it is clear margin performance continues to shape investor discussions around the business. See our full analysis for...

One thing we could say about the analysts on Pacific Edge Limited ( NZSE:PEB ) - they aren't optimistic, having just...

Ryman Healthcare (NZSE:RYM) has just reported H1 2026 financial results, posting total revenue of $806.7 million NZD and basic EPS of -0.64 NZD for the trailing twelve months. Historically, the company has seen revenue climb from $355.2 million NZD in H2 2024 to $394.0 million NZD by H2 2025. Basic EPS over recent halves ranged from -0.72 NZD to 0.14 NZD. Margins continue to face pressure as profitability remains elusive, making this an essential set of numbers for investors to digest. See...